Valneva

Lyme And Chikungunya Vaccines Will Capitalize On Rising Global Mobility

AnalystHighTarget

Not Invested

Consensus Narrative from 5 Analysts

Published

31 Aug 25

AnalystHighTarget's Fair Value

€9.50

60.0% undervalued

05 Sep

€3.80

20.9%

9.3%

20.9%

9.3%

Edit anytime before Aug 31 9:51 PM. Then post Updates to your followers.

Author's Valuation

€9.5

60.0% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

€9.5

60.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

19.26%

Biotech revenue growth rate

7.59%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.38%

Calculation

€336.62m

Earnings '28

9.38x

PE Ratio '28

€3.16b

Market Cap '28

€3.16b

Market Cap '28

276.35m

No. shares '28

€11.42

Share Price '28

€11.42 Share Price '28

Discounted to 2025 @ 6.34% p.a.

€9.50

Fair Value '25